Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07076121 · ClinicalTrials.gov registry record · Phase 2
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
A Phase 2 study of Pancreatic Ductal Adenocarcinoma, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 470
- Enrollment target
- 20
- Study locations
NCT07076121: Recruiting Phase 2 study of Pancreatic Ductal Adenocarcinoma, sponsored by Bristol-Myers Squibb.
NCT07076121 is a Phase 2 study of Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 470 participants, below the 595-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07076121, a Phase 2 study of Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 470 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in participants with untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC) with homozygous methylthioadenosine phosphorylase (MTAP) deletion.
Primary Outcome
Defined as the time between the randomization date and the date of progressive disease (PD) or death from any cause (whichever occurs first)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG BMS-986504
Study Locations (20)
Florida
- Local Institution - 0369 - Jacksonville
- Local Institution - 0139 - Jacksonville
- Local Institution - 0132 - Tampa
Arizona
- Local Institution - 0142 - Phoenix
- Local Institution - 0365 - Tucson
California
- Local Institution - 0373 - La Jolla
- Local Institution - 0157 - San Francisco
Georgia
- Local Institution - 0367 - Atlanta
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital - Marietta
Maryland
- Local Institution - 0371 - Baltimore
- Local Institution - 0145 - Baltimore
Michigan
- Local Institution - 0191 - Detroit
- The Cancer & Hematology Centers - Grand Rapids
Arkansas
- Highlands Oncology Group - Springdale
Idaho
- St. Luke's Cancer Institute: Boise - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 470 participants |
| Start Date | 2025-10-23 |
| Est. Completion | 2029-05-03 |
| Phase | Phase 2 |
What NCT07076121 shows while recruiting
NCT07076121 is an interventional study that assigns participants to a tested intervention. The registered 470 participants enrollment target is mid-sized for trials with a published cap, below the 595-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (21% lower).
The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT07076121 names 20 study sites across 13 states, led by Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT07076121 about?
NCT07076121 is a clinical study titled "A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)". The purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in participants with untreated metastatic Pancreatic Ductal Adenocarcin...
What is the current status of trial NCT07076121?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 470 participants. The study started on 2025-10-23. Estimated completion is 2029-05-03.
What conditions does trial NCT07076121 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT07076121?
The interventions under investigation include: Placebo (DRUG), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), BMS-986504 (DRUG).
Who is sponsoring clinical trial NCT07076121?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07076121 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07076121's enrollment target sits among peer trials
470 14th of 84 higher than 71 of 84 other Pancreatic Ductal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Ductal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 2
-
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
RECRUITING · Phase 2
-
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
RECRUITING · Phase 2
-
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05256940 · 470 participants · NA
Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide
- NCT05458219 · 470 participants · Phase 1
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
- NCT05850689 · 470 participants · Phase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- NCT05935384 · 470 participants
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI